Wedbush initiated coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $13.00 price objective on the biotechnology company’s stock.
Shares of ALPN opened at $9.95 on Thursday. The company has a current ratio of 26.70, a quick ratio of 43.67 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a twelve month low of $6.85 and a twelve month high of $12.87.
Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. The firm had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.13 million. research analysts expect that Alpine Immune Sciences will post -1.7 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. lifted its position in shares of Alpine Immune Sciences by 29.7% in the 4th quarter. Victory Capital Management Inc. now owns 51,551 shares of the biotechnology company’s stock worth $577,000 after purchasing an additional 11,799 shares during the period. Renaissance Technologies LLC lifted its position in shares of Alpine Immune Sciences by 29.9% in the 4th quarter. Renaissance Technologies LLC now owns 67,500 shares of the biotechnology company’s stock worth $756,000 after purchasing an additional 15,521 shares during the period. Wells Fargo & Company MN purchased a new stake in shares of Alpine Immune Sciences in the 4th quarter worth about $118,000. Finally, Millennium Management LLC purchased a new stake in shares of Alpine Immune Sciences in the 4th quarter worth about $205,000. 57.51% of the stock is owned by institutional investors and hedge funds.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.